Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.
Scheduled conference presentations in June include the following:
The 18th Annual Meeting of the RNA Society – Davos, Switzerland, June 14, 2013
A workshop presentation titled, “ Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA,” will be presented by Christine Wooddell, Ph.D., Senior Scientist;4th RNAi Research & Therapeutics Conference – San Francisco, CA, USA, June 21, 2013 A featured presentation titled, “ DPC Technology for siRNA Delivery: Moving from Platform to Pipeline,” will be presented by David Lewis, Ph.D., Vice President, Biology; The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine – Basel, Switzerland, June 26, 2013 An oral presentation titled, “ A Novel Hepatitis B Treatment with RNAi,” will be presented by Christopher Anzalone, Ph.D., President and CEO. About Arrowhead Research Corporation Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs. For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts